BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
Authors
Keywords
-
Journal
MOLECULES
Volume 28, Issue 7, Pages 3043
Publisher
MDPI AG
Online
2023-03-30
DOI
10.3390/molecules28073043
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent Advances in Dual BRD4‐Kinase Inhibitors Based on Polypharmacology
- (2022) Li Chen et al. ChemMedChem
- BET bromodomain inhibitors
- (2022) Martin P. Schwalm et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation‐induced profibrotic fibroblast responses
- (2022) Chun‐Shan Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical considerations for the design of PROTACs in cancer
- (2022) Cristina Nieto-Jiménez et al. Molecular Cancer
- Histone post-translational modifications — cause and consequence of genome function
- (2022) Gonzalo Millán-Zambrano et al. NATURE REVIEWS GENETICS
- A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles
- (2022) Hafiz Akbar Ali et al. Frontiers in Pharmacology
- Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2022) Rahul Aggarwal et al. CLINICAL CANCER RESEARCH
- BRD4 and MYC : power couple in transcription and disease
- (2022) Aparna Kotekar et al. FEBS Journal
- PROTACs for BRDs proteins in cancer therapy: a review
- (2022) Chao Wang et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity
- (2022) Xianghong Guan et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
- (2022) Mengjun Zhong et al. Cell Death & Disease
- NUT Carcinoma—An Underdiagnosed Malignancy
- (2022) Ulrich M. Lauer et al. Frontiers in Oncology
- A comprehensive review of BET-targeting PROTACs for cancer therapy
- (2022) Xiao-Li Zhou et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities
- (2022) Menglan Luo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
- (2022) Aqu Alu et al. Journal of Hematology & Oncology
- Co-Encapsulation of Paclitaxel and JQ1 in Zein Nanoparticles as Potential Innovative Nanomedicine
- (2022) Marilena Celano et al. Micromachines
- A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
- (2022) Mark A. Dawson et al. CLINICAL CANCER RESEARCH
- PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
- (2022) Nicolas Guedeney et al. DRUG DISCOVERY TODAY
- The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
- (2022) Si-Qi Jia et al. Journal of Immunology Research
- Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cure
- (2021) Edrous Alamer et al. Retrovirology
- Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
- (2021) Yanli Sun et al. Frontiers in Pharmacology
- A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome
- (2021) Gail J. Roboz et al. LEUKEMIA & LYMPHOMA
- Discovery and characterization of bromodomain 2–specific inhibitors of BRDT
- (2021) Zhifeng Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the acetylation signaling pathway in cancer therapy
- (2021) Fabin Dang et al. SEMINARS IN CANCER BIOLOGY
- A common binding motif in the ET domain of BRD3 forms polymorphic structural interfaces with host and viral proteins
- (2021) Sriram Aiyer et al. STRUCTURE
- Understanding the Function of Mammalian Sirtuins and Protein Lysine Acylation
- (2021) Miao Wang et al. Annual Review of Biochemistry
- Achieving clinical success with BET inhibitors as anti-cancer agents
- (2021) Tatiana Shorstova et al. BRITISH JOURNAL OF CANCER
- A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
- (2021) Gautam Borthakur et al. CANCER
- BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells
- (2021) Xiao Zhou et al. ONCOLOGY REPORTS
- Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges
- (2021) Kristine E. Yoder et al. Frontiers in Molecular Biosciences
- Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
- (2021) Shipeng He et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
- (2021) Renumathy Dhanasekaran et al. Nature Reviews Clinical Oncology
- Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
- (2021) Wenyu Wang et al. Nature Communications
- E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
- (2021) Aleša Bricelj et al. Frontiers in Chemistry
- Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
- (2021) Ming He et al. Frontiers in Cell and Developmental Biology
- Role of BET Proteins in Inflammation and CNS Diseases
- (2021) Lei Liu et al. Frontiers in Molecular Biosciences
- BRD4 in physiology and pathology: ‘‘BET’’ on its partners
- (2021) Yin Liang et al. BIOESSAYS
- Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I / II open‐label, dose escalation study
- (2021) Sophie Cousin et al. INTERNATIONAL JOURNAL OF CANCER
- BET Proteins as Attractive Targets for Cancer Therapeutics
- (2021) Joanna Sarnik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The intrinsic kinase activity of BRD4 spans its BD2-B-BID domains
- (2021) Jocelyn D. Weissman et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms
- (2021) Qianqian Wang et al. PHARMACOLOGICAL RESEARCH
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- Jumonji domain‐containing protein 6 protein and its role in cancer
- (2020) Jing Yang et al. CELL PROLIFERATION
- Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
- (2020) Emily J. Faivre et al. NATURE
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
- (2020) Marı́a Maneiro et al. ACS Chemical Biology
- Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms
- (2020) Qunying Jia et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- The therapeutic potential of BRD4 in cardiovascular disease
- (2020) Shigang Lin et al. HYPERTENSION RESEARCH
- Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain
- (2020) George S. Sheppard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation
- (2020) Zhiqing Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation
- (2020) Omer Gilan et al. SCIENCE
- Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
- (2020) Mingzhu Yin et al. Nature Communications
- BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response
- (2020) Janakiram R. Vangala et al. Biomolecules
- Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
- (2020) V. Moreno et al. ANNALS OF ONCOLOGY
- Bromodomain-selective BET inhibitors are potent antitumor agents against MYC-driven pediatric cancer
- (2020) P. Jake Slavish et al. CANCER RESEARCH
- BRD4 regulates key transcription factors that drive epithelial–mesenchymal transition in castration-resistant prostate cancer
- (2020) Jordan S. Shafran et al. PROSTATE CANCER AND PROSTATIC DISEASES
- A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression
- (2020) Zijun Zhou et al. Frontiers in Pharmacology
- A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity
- (2020) Adam M. Burgoyne et al. Cell Discovery
- An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers
- (2020) Kylie Riddell et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
- (2020) Geoffrey I. Shapiro et al. BRITISH JOURNAL OF CANCER
- FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
- (2020) Vanessa E. Kennedy et al. Frontiers in Oncology
- NUT carcinoma in a nutshell: A diagnosis to be considered more frequently
- (2019) Thomas Albrecht et al. PATHOLOGY RESEARCH AND PRACTICE
- BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses
- (2019) Anup Dey et al. EMBO JOURNAL
- Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants
- (2019) Michael Sebastian Ostertag et al. JOURNAL OF MOLECULAR BIOLOGY
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- A chemical toolbox for the study of bromodomains and epigenetic signaling
- (2019) Qin Wu et al. Nature Communications
- Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells
- (2019) Xin Li et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Molecular mechanisms of cereblon-based drugs
- (2019) Tomoko Asatsuma-Okumura et al. PHARMACOLOGY & THERAPEUTICS
- JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
- (2019) Matthew Wong et al. Nature Communications
- Degradation of proteins by PROTACs and other strategies
- (2019) Yang Wang et al. Acta Pharmaceutica Sinica B
- Light-Induced Protein Degradation with Photocaged PROTACs
- (2019) Gang Xue et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Bromodomain biology and drug discovery
- (2019) Nilesh Zaware et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo
- (2018) Kun Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
- (2018) Mark Wroblewski et al. HAEMATOLOGICA
- The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators
- (2018) Dorothy C. C. Wai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
- (2018) Jeremy Lewin et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition
- (2018) Guillaume P. Andrieu et al. MOLECULAR CANCER RESEARCH
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
- (2018) Sara Bolin et al. ONCOGENE
- Coactivator condensation at super-enhancers links phase separation and gene control
- (2018) Benjamin R. Sabari et al. SCIENCE
- The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
- (2018) Fang Xie et al. Scientific Reports
- BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
- (2018) Mark Wroblewski et al. HAEMATOLOGICA
- MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers
- (2018) Anastasia Wyce et al. Oncogenesis
- Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy
- (2018) Subhankar Biswas et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma
- (2018) Jixiang Shi et al. MOLECULAR PHARMACEUTICS
- Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
- (2018) Amanda Balboni Iniguez et al. CANCER CELL
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment
- (2018) Christopher A. French PATHOLOGY INTERNATIONAL
- The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
- (2017) Tania Díaz et al. HAEMATOLOGICA
- Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
- (2017) Stuart W. Ember et al. MOLECULAR CANCER THERAPEUTICS
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
- (2017) Pingzhao Zhang et al. NATURE MEDICINE
- Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
- (2017) Hana Janouskova et al. NATURE MEDICINE
- Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
- (2017) Takao Fujisawa et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner
- (2017) Vivek Kumar Mishra et al. NUCLEIC ACIDS RESEARCH
- Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis
- (2017) Forest H. Andrews et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis
- (2017) Jiahuan Chen et al. Nature Communications
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal (ET) Domain of BRD4
- (2017) Tsuyoshi Konuma et al. Scientific Reports
- The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
- (2017) Tania Díaz et al. HAEMATOLOGICA
- Targeting myeloid cells in the tumor sustaining microenvironment
- (2017) Jonathan Schupp et al. CELLULAR IMMUNOLOGY
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
- (2016) U.A. Matulonis et al. ANNALS OF ONCOLOGY
- AMPK–ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells
- (2016) Ji Eun Jang et al. CLINICAL CANCER RESEARCH
- The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
- (2016) J. Shahbazi et al. CLINICAL CANCER RESEARCH
- Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts
- (2016) Ramiro Vázquez et al. INTERNATIONAL JOURNAL OF CANCER
- The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo
- (2016) Sina Jostes et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective
- (2016) Luca Carlino et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)
- (2016) Robert H. Bradbury et al. JOURNAL OF MEDICINAL CHEMISTRY
- AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
- (2016) G. W. Rhyasen et al. MOLECULAR CANCER THERAPEUTICS
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Potent and selective bivalent inhibitors of BET bromodomains
- (2016) Michael J Waring et al. Nature Chemical Biology
- Design and characterization of bivalent BET inhibitors
- (2016) Minoru Tanaka et al. Nature Chemical Biology
- Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction
- (2016) Brandon L. Crowe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4
- (2016) Qiang Zhang et al. STRUCTURE
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
- (2016) A. Stathis et al. Cancer Discovery
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis
- (2016) Olga Aprelikova et al. Clinical Epigenetics
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
- (2016) Honorine Lebraud et al. ACS Central Science
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
- (2015) B. Sun et al. BLOOD
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties
- (2015) Chang-Ryul Lee et al. CARCINOGENESIS
- aBETting therapeutic resistance by Wnt signaling
- (2015) Carl G Engelke et al. CELL RESEARCH
- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
- (2015) Elodie Odore et al. CLINICAL PHARMACOKINETICS
- The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains
- (2015) Artyom A. Alekseyenko et al. GENES & DEVELOPMENT
- NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler
- (2015) Chen Shen et al. MOLECULAR CELL
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- Prime time for PROTACs
- (2015) Raymond J Deshaies Nature Chemical Biology
- What are super-enhancers?
- (2015) Sebastian Pott et al. NATURE GENETICS
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
- (2015) Lei-lei Fu et al. Oncotarget
- Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
- (2015) Anja Heinemann et al. Oncotarget
- BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
- (2015) Marie-Magdelaine Coudé et al. Oncotarget
- BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells
- (2015) Emma K Baker et al. Scientific Reports
- GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
- (2015) Krishan Kumar et al. Scientific Reports
- Role of JMJD6 in Breast Tumourigenesis
- (2015) Coralie Poulard et al. PLoS One
- Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
- (2014) Stuart W. J. Ember et al. ACS Chemical Biology
- SWI/SNF chromatin remodeling complexes and cancer
- (2014) Jaclyn A. Biegel et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS
- The bromodomain: From epigenome reader to druggable target
- (2014) Roberto Sanchez et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Comparative drug screening in NUT midline carcinoma
- (2014) A H Beesley et al. BRITISH JOURNAL OF CANCER
- Small Molecule Control of Chromatin Remodeling
- (2014) Aidan Finley et al. CHEMISTRY & BIOLOGY
- Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma
- (2014) Dhong Hyun Lee et al. INTERNATIONAL JOURNAL OF CANCER
- Mechanistic Analysis of the Role of Bromodomain-containing Protein 4 (BRD4) in BRD4-NUT Oncoprotein-induced Transcriptional Activation
- (2014) Ranran Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular mechanisms of retroviral integration site selection
- (2014) Mamuka Kvaratskhelia et al. NUCLEIC ACIDS RESEARCH
- Bimodal high-affinity association of Brd4 with murine leukemia virus integrase and mononucleosomes
- (2014) Ross C. Larue et al. NUCLEIC ACIDS RESEARCH
- BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
- (2014) Joydeep Bhadury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
- (2014) E. Seto et al. Cold Spring Harbor Perspectives in Biology
- NSD3-NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
- (2014) C. A. French et al. Cancer Discovery
- Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
- (2014) Jessica E. Bolden et al. Cell Reports
- JMJD6 Promotes Colon Carcinogenesis through Negative Regulation of p53 by Hydroxylation
- (2014) Feng Wang et al. PLOS BIOLOGY
- Regulation of chromatin structure via histone post-translational modification and the link to carcinogenesis
- (2013) Laura L. Thompson et al. CANCER AND METASTASIS REVIEWS
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release
- (2013) Wen Liu et al. CELL
- Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors
- (2013) Guillermo A. Morales et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bromo- and Extraterminal Domain Chromatin Regulators Serve as Cofactors for Murine Leukemia Virus Integration
- (2013) Saumya Shree Gupta et al. JOURNAL OF VIROLOGY
- BET proteins promote efficient murine leukemia virus integration at transcription start sites
- (2013) A. Sharma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma
- (2013) Ji Zhang et al. TUMOR BIOLOGY
- Small-Molecule Inhibition of BRDT for Male Contraception
- (2012) Martin M. Matzuk et al. CELL
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Cross-talk Among RNA Polymerase II Kinases Modulates C-terminal Domain Phosphorylation
- (2012) Ballachanda N. Devaiah et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Challenges in Vector and Trial Design Using Retroviral Vectors for Long-Term Gene Correction in Hematopoietic Stem Cell Gene Therapy
- (2012) Jacqueline Corrigan-Curay et al. MOLECULAR THERAPY
- Place your BETs: the therapeutic potential of bromodomains
- (2012) R.K. Prinjha et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Pathogenesis of NUT Midline Carcinoma
- (2011) Christopher A. French Annual Review of Pathology-Mechanisms of Disease
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Structural Basis and Specificity of Acetylated Transcription Factor GATA1 Recognition by BET Family Bromodomain Protein Brd3
- (2011) R. Gamsjaeger et al. MOLECULAR AND CELLULAR BIOLOGY
- The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3
- (2011) S. Rahman et al. MOLECULAR AND CELLULAR BIOLOGY
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
- (2010) P. Perez-Galan et al. BLOOD
- NUT midline carcinoma
- (2010) Christopher Alexander French CANCER GENETICS AND CYTOGENETICS
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- The Biology of Chromatin Remodeling Complexes
- (2009) Cedric R. Clapier et al. Annual Review of Biochemistry
- Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic Resolution
- (2009) Friederike Vollmuth et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription
- (2009) Anup Dey et al. MOLECULAR BIOLOGY OF THE CELL
- Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
- (2009) P. Hydbring et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
- (2009) C. Choudhary et al. SCIENCE
- Solution structure of the extraterminal domain of the bromodomain-containing protein BRD4
- (2008) Yi-Jan Lin et al. PROTEIN SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search